Literature DB >> 12063546

Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease.

Gaosheng Huang1, Qingguo Yan, Zhe Wang, Xiequn Chen, Xiaohui Zhang, Ying Guo, Jian Jian Li.   

Abstract

Although Epstein-Barr virus (EBV) infection has been implicated in the development of a subset of Hodgkin's disease, the etiology of EBV-negative Hodgkin's disease remains to be determined. We investigated the status of human cytomegalovirus (hCMV) infection in 42 cases of Hodgkin's disease in a Chinese population. Using a nested polymerase chain reaction assay, nine of the 42 cases (21.4%) were found to contain EBV DNA. While only one of the nine EBV-positive cases demonstrated amplifiable hCMV DNA, approximately 33.3% of the EBV-negative cases (11/33) showed molecular evidence of hCMV infection (8 mixed cellularity; 2 nodular sclerosis; and 1 lymphocyte depletion). All 17 lymph nodes with non-specific reactive changes were negative for hCMV DNA. The presence of hCMV in Reed-Sternberg cells and their variants was further confirmed by single-cell polymerase chain reaction, in situ hybridization and immunohistochemical analysis, which demonstrated ~50% amplified hCMV DNA. These results suggest for the first time that hCMV infection plays a potential role in signaling the cell transformation and pathogenesis of Hodgkin's disease, particularly in EBV-negative cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063546

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Lack of association of herpesviruses with brain tumors.

Authors:  S Poltermann; B Schlehofer; K Steindorf; P Schnitzler; K Geletneky; J R Schlehofer
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

2.  Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

Authors:  Devon J Shedlock; Kendra T Talbott; Stephan J Wu; Christine M Wilson; Karuppiah Muthumani; Jean D Boyer; Niranjan Y Sardesai; Sita Awasthi; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

3.  Detection of human cytomegalovirus in different histological types of gliomas.

Authors:  Michael E Scheurer; Melissa L Bondy; Kenneth D Aldape; Thomas Albrecht; Randa El-Zein
Journal:  Acta Neuropathol       Date:  2008-03-20       Impact factor: 17.088

4.  Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.

Authors:  Martin S Staege; Katja Müller; Stefanie Kewitz; Ines Volkmer; Christine Mauz-Körholz; Toralf Bernig; Dieter Körholz
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

Review 5.  The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials.

Authors:  Hsin-Pai Chen; Yu-Jiun Chan
Journal:  Front Oncol       Date:  2014-11-17       Impact factor: 6.244

Review 6.  US28: HCMV's Swiss Army Knife.

Authors:  Benjamin A Krishna; William E Miller; Christine M O'Connor
Journal:  Viruses       Date:  2018-08-20       Impact factor: 5.048

Review 7.  The role of CMV in glioblastoma and implications for immunotherapeutic strategies.

Authors:  Maryam Rahman; Farhad Dastmalchi; Aida Karachi; Duane Mitchell
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 8.  The constitutive activity of the viral-encoded G protein-coupled receptor US28 supports a complex signalling network contributing to cancer development.

Authors:  Carole A Daly; Martine J Smit; Bianca Plouffe
Journal:  Biochem Soc Trans       Date:  2020-08-28       Impact factor: 5.407

9.  Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients.

Authors:  Edyta Paradowska; Agnieszka Jabłońska; Mirosława Studzińska; Miłosz Wilczyński; Jacek R Wilczyński
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

Review 10.  Immune Landscape of CMV Infection in Cancer Patients: From "Canonical" Diseases Toward Virus-Elicited Oncomodulation.

Authors:  Ranim El Baba; Georges Herbein
Journal:  Front Immunol       Date:  2021-09-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.